NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy

The rationale for treating patients with early stage HR-positive breast cancer with extended adjuvant therapy based on lessons learned through clinical trial evidence and real-world practice.

An overview of predictive and prognostic biomarkers used by breast oncologists to aid in adjuvant treatment decisions for HR-positive disease, as outlined by the NCCN guidelines.

Lee Schwartzberg, MD, FACP, of West Cancer Center & Research Institute, discusses the role of genomic testing in hormone receptor-positive breast cancer and compares information provided by various assays approved for use.

Common scenarios for which genomic testing is recommended to aid in treatment decisions for patients with hormone receptor-positive breast cancer.

Dr. Lee Schwartzberg highlights recent changes to the NCCN guidelines in terms of guidance for genomic testing in HR-positive breast cancer based on updates to the RxPONDER trial and data supporting the use of the Breast Cancer Index.

Current recommendations for conducting genomic testing in patients with HR+ [hormone receptor-positive] breast cancer, as outlined by the NCCN clinical practice guidelines.

Dr. Lee Schwartzberg comments on unmet needs in the treatment of early-stage HR+ [hormone receptor-positive] breast cancer.

This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.